WILMINGTON, Mass.--(BUSINESS WIRE)--
Charles
River Laboratories International, Inc. (NYSE: CRL) today announced
that its team of leading Central Nervous System (CNS) and neurological
disease experts is presenting 25 scientific posters and one podium
presentation, both independently and collaboratively with clients, at Neuroscience
2016, the annual meeting of the Society
for Neuroscience (SfN). The meeting, which brings together over
30,000 researchers from more than 80 countries, is taking place from
November 12-16 in San Diego, California.
"The field of neuroscience is rapidly changing and evolving," said
Patrick Sweeney, Managing Director of Charles River Discovery Services.
"At this year's conference, we will host two scientific discussions on
the development of therapeutics for aging and the in vitro and in
vivo aspects of drug discovery. We see Neuroscience 2016 as an
important opportunity for our experts to collaborate with top scientists
from across the globe, sharing our scientific expertise and learning
from colleagues."
Among the posters the Charles River team will present are innovative
tools and applications for research targeting Huntington's, Alzheimer's,
Parkinson's, Multiple Sclerosis, Duchenne Muscular Dystrophy, and other
neurological disorders. Noteworthy examples include:
-
A collaboration with the University of Eastern Finland and Kuopio
University Hospital on the use of dynamic PET imaging. (Dynamic PET
Imaging with Arterial Input Function of Lipopolysaccharide-Induced
Neuroinflammation in Rat)
-
A collaboration with Cure Huntington's Disease Initiative (CHDI) on
the utilization of Rho kinase inhibitors for Huntington's disease
therapeutics. (Progress Towards Potent, Selective and Brain Penetrant
Rho Kinase Inhibitors Suitable for a Proof-of-Concept Study in HD
Models)
-
The study of altered nerve cell function in Huntington's disease
models. (Investigation of Corticostriatal Synaptic Transmission and
Cerebellar Purkinje Neuron Firing in the R6/2 Mouse Model of
Huntington's Disease by Using Multi-Electrode Arrays)
Additionally, the Charles River team, in conjunction with Sage
Therapeutics, will participate in a nanosymposium titled "Epilepsy:
Mechanisms" to discuss an optimized high-throughput screening approach
to identify positive allosteric modulators of N-methyl-D-aspartate
glutamate receptors (NMDARs), which are promising therapeutic targets
for numerous neurological indications. This symposium will be held on
Monday, November 14, 2016. Nikolai Fedorov, Principal Scientist,
Discovery Screening Services at Charles River, will present at 10:00am
PST. As a part of its continued focus on high-throughput screening as a
mechanism for studying CNS, Charles River recently expanded its ion
channel capabilities through the addition of a Sophion Qube 384-well
automated patch-clamp platform.
A full schedule of Charles River's activities during Neuroscience 2016
is available on our website,
and reprints of each poster are available in Charles River's booth
(#1619) during the conference. Additionally, CNS experts are available
for meetings with those interested in discussing neuroscience research
and drug discovery. Throughout the conference, Charles River will be
providing live updates on the Eureka
Blog, including reviews of scientific sessions and input on the
research being presented.
About the Society for Neuroscience
The Society
for Neuroscience is the world's largest organization of scientists
and physicians devoted to understanding the brain and nervous system.
The nonprofit organization, founded in 1969, now has nearly 40,000
members in more than 90 countries and 130 chapters worldwide.
About Charles River
Charles River provides essential products and services to help
pharmaceutical and biotechnology companies, government agencies and
leading academic institutions around the globe accelerate their research
and drug development efforts. Our dedicated employees are focused on
providing clients with exactly what they need to improve and expedite
the discovery, early-stage development and safe manufacture of new
therapies for the patients who need them. To learn more about our unique
portfolio and breadth of services, visit www.criver.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161110005170/en/
